Virtus ETF Advisers’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $457K | Buy |
2,714
+130
| +5% | +$19.3K | 0.18% | 147 |
|
|
2026
Q1 | $340K | Hold |
2,584
| – | – | 0.16% | 161 |
|
|
2025
Q4 | $366K | Hold |
2,584
| – | – | 0.17% | 147 |
|
|
2025
Q3 | $363K | Hold |
2,584
| – | – | 0.2% | 136 |
|
|
2025
Q2 | $325K | Hold |
2,584
| – | – | 0.2% | 138 |
|
|
2025
Q1 | $286K | Sell |
2,584
-174
| -6% | -$22K | 0.19% | 158 |
|
|
2024
Q4 | $376K | Buy |
2,758
+341
| +14% | +$42.2K | 0.15% | 190 |
|
|
2024
Q3 | $278K | Hold |
2,417
| – | – | 0.13% | 234 |
|
|
2024
Q2 | $333K | Sell |
2,417
-723
| -23% | -$99.2K | 0.16% | 209 |
|
|
2024
Q1 | $433K | Buy |
3,140
+452
| +17% | +$61.7K | 0.23% | 187 |
|
|
2023
Q4 | $354K | Sell |
2,688
-539
| -17% | -$62K | 0.22% | 185 |
|
|
2023
Q3 | $363K | Sell |
3,227
-420
| -12% | -$44.2K | 0.22% | 187 |
|
|
2023
Q2 | $344K | Buy |
3,647
+1,062
| +41% | +$104K | 0.2% | 159 |
|
|
2023
Q1 | $262K | Buy |
2,585
+48
| +2% | +$5K | 0.14% | 272 |
|
|
2022
Q4 | $303K | Sell |
2,537
-45
| -2% | -$5.27K | 0.16% | 262 |
|
|
2022
Q3 | $274K | Buy |
2,582
+38
| +1% | +$3.86K | 0.11% | 284 |
|
|
2022
Q2 | $248K | Sell |
2,544
-1,953
| -43% | -$180K | 0.09% | 299 |
|
|
2022
Q1 | $422K | Hold |
4,497
| – | – | 0.19% | 149 |
|
|
2021
Q4 | $383K | Sell |
4,497
-97
| -2% | -$8.92K | 0.14% | 167 |
|
|
2021
Q3 | $441K | Sell |
4,594
-418
| -8% | -$39.5K | 0.19% | 157 |
|
|
2021
Q2 | $488K | Sell |
5,012
-1,680
| -25% | -$161K | 0.2% | 155 |
|
|
2021
Q1 | $651K | Buy |
6,692
+180
| +3% | +$18.9K | 0.28% | 116 |
|
|
2020
Q4 | $624K | Buy |
6,512
+1,421
| +28% | +$137K | 0.26% | 101 |
|
|
2020
Q3 | $490K | Buy |
5,091
+284
| +6% | +$32.9K | 0.26% | 140 |
|
|
2020
Q2 | $587K | Sell |
4,807
-515
| -10% | -$56.9K | 0.28% | 122 |
|
|
2020
Q1 | $461K | Sell |
5,322
-449
| -8% | -$43.9K | 0.19% | 178 |
|
|
2019
Q4 | $620K | Sell |
5,771
-2,479
| -30% | -$260K | 0.1% | 184 |
|
|
2019
Q3 | $743K | Sell |
8,250
-1,396
| -14% | -$130K | 0.15% | 158 |
|
|
2019
Q2 | $814K | Sell |
9,646
-1,025
| -10% | -$84.2K | 0.17% | 181 |
|
|
2019
Q1 | $940K | Buy |
10,671
+2,386
| +29% | +$199K | 2% | 11 |
|
|
2018
Q4 | $592K | Buy |
8,285
+462
| +6% | +$44.3K | 0.1% | 47 |
|
|
2018
Q3 | $962K | Buy |
7,823
+527
| +7% | +$59.8K | 0.1% | 54 |
|
|
2018
Q2 | $717K | Sell |
7,296
-5,603
| -43% | -$502K | 0.63% | 92 |
|
|
2018
Q1 | $1.07M | Sell |
12,899
-753
| -6% | -$63.6K | 0.93% | 31 |
|
|
2017
Q4 | $1.06M | Sell |
13,652
-9,899
| -42% | -$675K | 1.33% | 9 |
|
|
2017
Q3 | $1.44M | Hold |
23,551
| – | – | 0.19% | 36 |
|
|
2017
Q2 | $1.08M | Buy |
23,551
+17,076
| +264% | +$828K | 0.16% | 56 |
|
|
2017
Q1 | $280K | Buy |
6,475
+621
| +11% | +$26.6K | 0.05% | 145 |
|
|
2016
Q4 | $227K | Buy |
5,854
+530
| +10% | +$24K | 0.07% | 162 |
|
|
2016
Q3 | $270K | Hold |
5,324
| – | – | 0.13% | 112 |
|
|
2016
Q2 | $242K | Buy |
5,324
+564
| +12% | +$26K | 0.18% | 99 |
|
|
2016
Q1 | $188K | Buy |
+4,760
| New | +$189K | 0.26% | 94 |
|
Other funds holding NBIX
Virtus ETF Advisers's NBIX Position: Q2 2026 in Review
Virtus ETF Advisers increased its Neurocrine Biosciences (NBIX) stake by 5% in Q2 2026, buying an estimated $19.3K and bringing the position to 2,714 shares worth $457K. The position accounts for 0.18% of the portfolio, ranked #147.
Virtus ETF Advisers first reported a position in NBIX in Q1 2016 and has held it in 42 quarters since. The position peaked at $1.44M in Q3 2017. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Virtus ETF Advisers held 2,714 shares of Neurocrine Biosciences worth $457K as of Q2 2026.
- Virtus ETF Advisers bought 130 Neurocrine Biosciences shares in Q2 2026, an estimated $19.3K.
- Neurocrine Biosciences made up 0.18% of Virtus ETF Advisers's portfolio in Q2 2026, its #147 holding.
- Virtus ETF Advisers first reported a position in Neurocrine Biosciences in Q1 2016 and has held it in 42 quarters since.
- Virtus ETF Advisers's Neurocrine Biosciences position peaked at $1.44M in Q3 2017.
- 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.